Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01912001
Other study ID # 12-5397-AE
Secondary ID
Status Recruiting
Phase N/A
First received July 22, 2013
Last updated December 7, 2015
Start date September 2013
Est. completion date March 2016

Study information

Verified date December 2015
Source University Health Network, Toronto
Contact Christopher T Chan, MD
Phone 416 340-3073
Email Christopher.Chan@uhn.ca
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

Home based renal replacement therapy (RRT), including peritoneal dialysis (PD) and home hemodialysis(HHD), offers enhanced quality of life and clinical advantages compared to conventional in-center hemodialysis. Patients with end stage renal disease, that is failure of the kidneys such that dialysis is required, are at high risk for adverse health events especially during a period of transition following a change in care settings. The investigators aim to implement a Home Dialysis Virtual Ward (HDVW) strategy of telephone follow-up, which is targeted to minimize gaps of care during transitions in care.

The investigators aim to have clinicians follow patients by telephone if they meet one of the following four criteria;

1. Discharge from hospital.

2. Having an interventional procedure.

3. Prescription of an antibiotic.

4. Completion of Home Dialysis training.

The major goal of this HDVW initiative is to provide appropriate and effective supports to medically complex patients in a targeted window of vulnerability.


Description:

End stage renal disease (ESRD) is kidney disease that requires dialysis or kidney transplant to replace lost kidney function. The most common renal replacement therapy in North America is conventional, in-center hemodialysis (CHD). Home dialysis - including peritoneal dialysis (PD) and home hemodialysis(HHD)offers benefits to quality of life, patient satisfaction and clinical advantages, including better survival compared to CHD. (references 1-11 in the protocol).

Patients with (ESRD) have a high burden of co-morbidity. Periods of transition of care from acute care to other settings are thought to represent times of increased vulnerability. Since patients who require home dialysis have high co-morbidity and have complex medical care issues, the investigators seek to improve transitions of care for these patients with a novel strategy of follow-up.

When patients have been hospitalized, had treatment for an infection, had a procedure, or have just transitioned to home dialysis therapy,the investigators aim to decrease gaps in care by having a clinician follow-up by telephone with these patients in a scheduled way.

During the telephone call the clinician will assess the patients care and symptoms, and make adjustments to prescriptions of medications and dialysis, or referrals to additional care as required. Evaluation of care will include:

1. Indication for admission to the Virtual Ward.

2. Dialysis prescription.

3. Demographic and comorbidity data.

4. Medication reconciliation.

5. Symptom Assessment.

6. Dietary review.

Symptoms will be evaluated using a standardized patient assessment tool,the Charlson Comorbidity Index and the modified Edmonton Symptom Assessment Scale.

At the end of the Virtual Ward follow-up period, patients will be asked to complete a Patient Satisfaction Questionnaire.

Data from a preliminary vanguard pilot phase of 84 assessments done in 21 patients over 2 months indicates that 170 to 200 patients recruited from eight sites during a 10 month period should be sufficient to allow analysis of the data collected.

Each of the participating Investigator's will have input into the study conduct and publication preparation.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date March 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient in the home dialysis program (PD and HHD)and on of the following:

- Discharge from hospital following an inpatient admissions

- Medical procedure (e.g. vascular access procedure).

- Treatment with antibiotics.

- Completion of home dialysis training program.

Exclusion Criteria:

- Decline consent.

- Unable to participate - (e.g. no phone at home, language barrier)

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Other:
Telephone follow-up

Sympton Assessment


Locations

Country Name City State
Canada University of Alberta Edmonton Alberta
Canada Capital District Health Authority Halifax Nova Scotia
Canada The Ottawa Hospital Ottawa Ontario
Canada St. Michael's Hospital Toronto Ontario
Canada Sunnybrook Health Sciences Centre Toronto Ontario
Canada University Health Network Toronto Ontario
Canada Vancouver General Hospital Vancouver British Columbia

Sponsors (9)

Lead Sponsor Collaborator
Christopher Chan Baxter Healthcare Corporation, Capital Health Nova Scotia, St. Michael's Hospital, Toronto, St. Paul's Hospital, Canada, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University of Alberta, Vancouver General Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of care gaps identified. Up to 24 weeks post discharge from the virtual ward. Yes
Secondary Dialysis prescription and adherence. Orders for dialysis treatment and amount of dialysis performed will be recorded. Up to 24 weeks. Yes
Secondary Morbidity associated with dialysis therapy. All deaths will be recorded. Up to 24 weeks post discharge from the virtual ward. Yes
Secondary Burden associated with travel time for patients. Travel time for health related visits will be recorded. Up to 24 weeks post discharge from the virtual ward. Yes
Secondary Medication reconciliation. Best possible medication history will be recorded at each interaction. Up to 24 weeks post discharge from the virtual ward. Yes
Secondary Symptom management. Symptom assessment will be done at each interaction. Up to 24 weeks post discharge from the virtual ward. Yes
Secondary Adherence with dietary recommendations. Diet review will be performed at each visit. Up to 24 weeks post discharge from the virtual ward. Yes
Secondary Coordination of care among participating providers. Referrals and consultations will be tracked. During virtual ward follow-up. Yes
Secondary Patient satisfaction. A satisfaction questionnaire will be mailed to participants at the end of participation. 24 weeks post discharge from the virtual ward. No
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Terminated NCT02924298 - Effect of Sit Less, Interact, Move More (SLIMM) Regimen on Patients With Chronic Kidney Disease (CKD) N/A